v3.26.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Equity, beginning balance at Jun. 30, 2024 $ 9 $ 335,162   $ (313,847) $ 21,324
Equity, beginning balance (shares) at Jun. 30, 2024 8,624,000        
Common stock issued $ 4 3,642     3,646
Common stock issued (shares) 4,744,000        
Exercise of stock options $ 0 130     $ 130
Exercise of stock options (shares) 73,000       73,100
Vesting of RSUs $ 0        
Vesting of RSUs (shares) 35,000        
Share-based compensation   1,530     $ 1,530
AstrialBio Exclusive License Agreement shares issued $ 0 750     750
AstrialBio Exclusive License Agreement shares issued (shares) 246,000        
Warrant Inducement Transaction $ 6 5,871     5,877
Warrant Inducement Transaction (in shares) 5,627,000        
Net loss       (18,377) (18,377)
Equity, ending balance at Jun. 30, 2025 $ 19 347,085   (332,224) 14,880
Equity, ending balance (shares) at Jun. 30, 2025 19,349,000        
Common stock issued $ 37 17,972     $ 18,009
Common stock issued (shares) 36,349,000        
Exercise of stock options (shares)         0
Vesting of RSUs $ 0 0     $ 0
Vesting of RSUs (shares) 0        
Share-based compensation   1,373     1,373
Issuance of pre-funded warrants   84,540     84,540
Unrealized loss on available-for-sale debt securities     $ (45)   (45)
Net loss       (33,044) (33,044)
Equity, ending balance at Jun. 30, 2026 $ 56 $ 450,970 $ (45) $ (365,268) $ 85,713
Equity, ending balance (shares) at Jun. 30, 2026 55,698,000